Background
Flexicath has developed a special intravenous (IV) catheter that can be used for treatment periods of up to 15 days – the treatment period in 80% to 90% of patients requiring IV therapy.
The catheter can be adapted to specific patients without requiring a new insertion site.
The total estimated world market for peripheral IV catheters is approximately $1 billion.
Technology
Intravenous therapy delivers fluids and medications to the patient through a hollow tube inserted into the patient’s vein. The procedure enables the delivery of therapeutic agents directly into the bloodstream, allowing optimal and immediate results. The port of entry is the IV catheter, inserted peripherally into the vein. There are two types of IV catheters in common use: short-term catheters, which are used for period of up to three days (and then replaced), and long-term venous catheters, which are user for periods of longer than one month.
The Flexicath advantages --
- Can be inserted through the existing port of entry
- Adapts to specific patient without new insertion site
- Incorporates an inexpensive insertion technique with built-in sterile field
- Reduces risk of vein inflammation and perforation
TEAM
Shai Amisar, CEO
Ronen Radomski, CTO
Prof. Paul Froom
|
 |
| Contact Us |
|
|
|
| Development Status
|
Flexicath joined Misgav in August 2004. The company has developed several concepts of its clever insertion unit and is in the process of patenting them. Development has started on one of these concepts and a working prototype should be available in early-Q2 2005. A pre-development clinical study, with the participation of world-leading Teva Pharmaceutical, is expected to begin in March 2005.
|
|
Medical Devices